Ginsenosides Show Promise Against Neurodegenerative Diseases by Blocking Ferroptosis

Ginseng has sat at the intersection of folklore and pharmacology for more than two thousand years, prized across East Asia as a restorative root and studied in Western laboratories as a source of biologically active molecules. A new analysis now argues that the herb’s signature compounds may do something with direct relevance to some of medicine’s most stubborn diseases: block a form of cell death that appears to help drive Alzheimer’s, Parkinson’s and motor-neuron disorders. In a narrative review published on 29 August 2026 in Molecular Biology Reports, Chang Liu and Yanru Zhang of the School of Medicine at Ningbo University in China assembled evidence that ginsenosides—the principal bioactive triterpenoid saponins extracted from plants of the Panax genus—can suppress ferroptosis, an iron-dependent mode of cell death increasingly implicated in neurodegeneration. Drawing on systematic searches of PubMed, Web of Science and Scopus that used both MeSH terms and free-text keywords, the pair winnowed more than 400 papers published between 1998 and 2026 down to 107 studies, concluding that ginsenosides hold genuine promise as modulators of iron homeostasis in the aging brain.

Ferroptosis, formally named in 2012, is unlike any other form of regulated cell death. Apoptosis disassembles a cell with tidy efficiency; necrosis bursts it messily; ferroptosis corrodes it. Iron, abundant and chemically reactive inside cells, catalyzes the peroxidation of membrane phospholipids rich in polyunsaturated fatty acyl tails—work published in Cell in 2024 showed that phospholipids carrying two such tails are especially potent ferroptosis fuels. As lipid hydroperoxides accumulate, membranes lose their integrity and the cell collapses. The pathway’s central brake is glutathione peroxidase 4 (GPX4), the only mammalian enzyme known to reduce oxidized lipids inside membranes, which depends on a steady supply of cystine imported through the transporter xCT. Backup systems exist, including the FSP1–coenzyme Q10 pathway that regenerates antioxidant capacity independently of GPX4 and the mitochondrial enzyme DHODH. Research in Nature in 2024 demonstrated that ferroptosis can propagate through tissue in “trigger waves,” killing cells at a distance, and a 2025 Cell study traced neuroprotection from ferroptosis to a fin-loop-like structure within GPX4 itself—testimony to how tightly neuron survival is bound to this single enzyme.

The link to neurodegeneration rests on a sobering convergence of facts. Human brains are among the most lipid-rich and oxygen-hungry organs in the body, densely stocked with the polyunsaturated fats that ferroptosis consumes. Iron, meanwhile, accumulates with age in precisely the regions that neurodegenerative diseases attack: the substantia nigra in Parkinson’s disease, the basal ganglia in Huntington’s disease, and the motor cortex and thalamus in amyotrophic lateral sclerosis, where quantitative susceptibility MRI has detected deposits that track with clinical severity. A 2024 review in Nature Reviews Neuroscience described how certain neuron populations are selectively vulnerable to molecular stress, and ferroptosis researchers have argued that this cell-death pathway acts not merely as an epiphenomenon but as an orchestrator of degeneration. Liu and Zhang frame the problem as a global public health imperative: as populations age, the prevalence of Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis climbs, yet current clinical interventions remain limited, doing little to correct iron overload or lipid peroxidation at their source.

The disease-by-disease evidence is substantial. In Alzheimer’s disease, an autopsy study published in 2025 found that ferroptosis-induced structural changes in cerebral microvasculature contribute to blood–brain barrier breakdown, while separate work showed that microglia lacking the autophagy gene ATG7 undergo ferroptosis and lose their ability to restrain amyloid pathology. Even gut microbes appear to weigh in: microbiota-derived lysophosphatidylcholine alleviates Alzheimer’s pathology by suppressing ferroptosis, and aberrant mitochondrial metabolism has been linked directly to ferroptotic stress in the disease. In Parkinson’s disease, the toxic interaction between α-synuclein aggregates and iron induces cellular senescence before nigral dopaminergic neurons are lost, and ferroptosis inhibition protects against α-synuclein-related neuronal death in experimental models. In ALS, ferroptosis has been shown to mediate selective motor neuron death, and activating NRF2 suppresses motor-neuron ferroptosis driven by the SOD1G93A mutation. Huntington’s disease features ALOX5-mediated ferroptosis under oxidative stress, and in multiple sclerosis pharmacological targeting of ferroptosis suppresses experimental disease progression—an unusually broad footprint for a single cell-death pathway.

Into this picture walk the ginsenosides. These amphiphilic molecules share a dammarane-type triterpenoid scaffold decorated with sugar chains, and are conventionally divided into protopanaxadiol-type members such as Rb1, Rb2, Rb3, Rc, Rd and Rg3, and protopanaxatriol-type members such as Rg1 and Re. Heat-processing of ginseng—the traditional steaming that yields “red ginseng”—converts abundant major ginsenosides into rarer minor derivatives such as Rk1, Rg5 and Rk3, which laboratory studies suggest are more potent, while human gut bacteria transform ingested ginsenosides into compound K, a metabolite with strong anti-inflammatory activity. The review catalogs an unusually wide pharmacological repertoire: antitumor, immunomodulatory, anti-inflammatory, anti-allergic, anti-atherosclerotic, antihypertensive, antidiabetic, antistress and neuroprotective activities have all been reported. Chemists have long noted their antioxidant behavior—a 2012 analysis in Chemical Reviews positioned ginseng as a natural resource for antioxidants—and recent work shows that ginsenosides can act simultaneously as drugs and as self-assembling nanocarriers for other therapeutics, a dual identity that few natural products share.

The review’s central mechanistic claim is that ginsenosides influence neurodegeneration chiefly by modulating ferroptosis, and their molecular entry points map onto the pathway’s known control circuits. The dominant upstream target is NRF2, the transcription factor that switches on genes for glutathione synthesis, iron storage and cystine import. Ginsenoside RK1 improved cognitive impairments and pathological changes in Alzheimer’s models by stimulating the AMPK/Nrf2 signaling pathway; Rk3 ameliorated amyloid-β neurotoxicity through the same axis; and Rg1 alleviated chronic inflammation-induced neuronal ferroptosis and cognitive deficits by regulating an AIM2–Nrf2 pathway. Compound K, the gut-derived metabolite, alleviated brain aging by inhibiting ferroptosis through modulation of the ASK1–MKK7–JNK cascade, a stress-kinase route that converges on the ferroptotic machinery. Beyond NRF2, Rg5 interfered with an autophagy/Nrf2/ferroptosis signal axis, and Rb1 engaged an NRF2–PPARγ–ACSL4 axis—ACSL4 being the enzyme that loads polyunsaturated fatty acids into membrane phospholipids, in effect stocking ferroptosis’s fuel supply.

Other ginsenosides act closer to the lipid membrane and the labile iron pool. In a 2024 study in Advanced Science, ginsenoside Rg3 restored mitochondrial cardiolipin homeostasis via the adaptor protein GRB2 to prevent Parkinson’s disease—a significant result, because cardiolipin is the iron-sensitive mitochondrial lipid whose peroxidation helps ignite ferroptosis. Rg1 has been shown to regulate iron-regulated proteins and counter lipid peroxidation in oligodendrocytes, the myelin-building cells increasingly described as guardians of brain iron homeostasis. Ginsenoside Rd inhibited ferroptosis after subarachnoid hemorrhage by acting through the cGAS/STING/DHODH pathway, linking inflammatory DNA-sensing to lipid defense; Re upregulated the GPX4/xCT axis in endothelial cells exposed to homocysteine; and Rg1 suppressed ferroptosis via the FSP1–CoQ10–NAD(P)H salvage pathway in models of acute kidney injury. Notably, the same chemistry can cut both ways: Rg3 induces ferroptosis in melanoma cells through the p53/SLC7A11/GPX4 pathway, suggesting that ginsenosides might one day be tuned to protect neurons while helping destroy tumors.

Delivering these molecules to the brain remains the field’s central bottleneck. Ginsenosides suffer from poor oral bioavailability, rapid metabolism and limited penetration of the blood–brain barrier, and the review catalogues the countermeasures now under development: pre-processing and structural modification to create more potent derivatives, drug combinations, and micro- or nano-scale delivery systems. Combination strategies look promising—ginkgo biloba extract increased the brain uptake of ginsenosides by opening the barrier through A1 adenosine receptor signaling, and proliposome formulations have improved oral absorption. Nanotechnology offers another route: Rg1 nanoparticles engineered to cross the blood–brain barrier improved cerebral function in diabetic rats with cerebral infarction, while parallel ferroptosis-directed programs are testing intranasal delivery of gallium–quercetin nanoparticles and transferrin receptor-targeted liposomes in models of Parkinson’s disease and traumatic brain injury. Because ginsenosides are amphiphilic, they can themselves form nanocarriers, and the gut microbiota—through which compound K and related metabolites are born—emerges as both a metabolic factory and a therapeutic target along the brain–gut axis.

Caveats temper the enthusiasm. Nearly all of the mechanistic work summarized in the review comes from cell cultures and animal models; human evidence remains thin. One small clinical study did find that heat-processed ginseng enhanced cognitive function in patients with moderately severe Alzheimer’s disease, but rigorous, adequately powered trials are lacking, and questions of dosing, extract standardization and ginsenoside identity remain unresolved. There is also a biological tension to manage: ferroptosis is not simply an enemy. The pathway helps eliminate damaged cells and can be harnessed against cancer, as the melanoma data show, so indiscriminate systemic inhibition carries unknown risks. The authors received no funding and declare no competing interests, and their paper is explicitly a synthesis rather than a clinical demonstration. Even so, the wider therapeutic landscape supports the concept: iron chelators such as deferoxamine, delivered by engineered nanosheets or rabies-virus-glycoprotein-modified nanoparticles, have reversed functional deficits in parkinsonian mice, and drugs that mitigate ferroptosis have shown neuroprotection in Huntington’s disease models.

What emerges from Liu and Zhang’s synthesis is the convergence of two research currents that once ran separately: phytochemistry and cell-death biology. Ferroptosis has given neuroscientists a mechanistic lens on why aging brains lose specific neurons; ginsenosides—ancient, chemically rich and increasingly well characterized—may give pharmacologists a multi-point toolkit that touches iron handling, lipid metabolism, NRF2 signaling and mitochondrial integrity at once. The review stops short of clinical claims, but it sketches a translational roadmap: identify the most potent ginsenoside derivatives, standardize their production through controlled heat-processing or microbial biotransformation, engineer delivery systems that cross the blood–brain barrier, and test whether ferroptosis-related markers—brain iron deposits and oxidized lipid signals—can track treatment response in patients. If those steps succeed, a root that traditional medicine has brewed for centuries could be recast as a precision instrument against some of the most feared diseases of aging. For now the message is narrower but striking: the chemistry of ginseng and the biology of ferroptosis appear, for the first time, to be speaking the same molecular language.